Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience

Banu Atalar, Mahmut Ozsahin, Jason Call, Aleksandra Napieralska, Serra Kamer, Salvador Villa, Petek Erpolat, Laura Negretti, Yasmin Lassen-Ramshad, Cem Onal, Serap Akyurek, Gamze Ugurluer, Brigitta G. Baumert, Stephanie Servagi-Vernat, Robert C. Miller, Enis Ozyar, Terence T. Sio

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)96-102
Number of pages7
JournalRadiotherapy and Oncology
Volume127
Issue number1
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • Adult medulloblastoma
  • Chemotherapy
  • Craniospinal
  • Multimodality
  • Radiotherapy
  • Rare Cancer Network (RCN)
  • NONMETASTATIC MEDULLOBLASTOMA
  • ADJUVANT CHEMOTHERAPY
  • RISK MEDULLOBLASTOMA
  • SURVIVAL
  • MULTICENTER
  • RECURRENCE
  • STRATEGY

Cite this

Atalar, B., Ozsahin, M., Call, J., Napieralska, A., Kamer, S., Villa, S., Erpolat, P., Negretti, L., Lassen-Ramshad, Y., Onal, C., Akyurek, S., Ugurluer, G., Baumert, B. G., Servagi-Vernat, S., Miller, R. C., Ozyar, E., & Sio, T. T. (2018). Treatment outcome and prognostic factors for adult patients with medulloblastoma: The Rare Cancer Network (RCN) experience. Radiotherapy and Oncology, 127(1), 96-102. https://doi.org/10.1016/j.radonc.2017.12.028